<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090644</url>
  </required_header>
  <id_info>
    <org_study_id>1203</org_study_id>
    <nct_id>NCT05090644</nct_id>
  </id_info>
  <brief_title>Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group</brief_title>
  <official_title>Preventive and Personalized Medicine (2021-2023)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asfendiyarov Kazakh National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asfendiyarov Kazakh National Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a GWAS study that aims to identify possible candidate genes associate to&#xD;
      schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia,&#xD;
      in the Kazakh population. The investigators hypothesize that the careful phenotyping of the&#xD;
      subject sand matching with increase the power to find SNP significantly associated with&#xD;
      schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A genome-wide association study (GWAS) is an approach used in genetics research to associate&#xD;
      specific genetic variations with particular diseases. The method involves scanning the&#xD;
      genomes from many different people and looking for genetic markers that can be used to&#xD;
      predict the presence of a disease. Once such genetic markers are identified, they can be used&#xD;
      to understand how genes contribute to the disease and develop better prevention and treatment&#xD;
      strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of SNPs associated with schizophrenia</measure>
    <time_frame>1 year</time_frame>
    <description>Using GWAS to identify candidate genes associate with schizophrenia</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Experimental group:</arm_group_label>
    <description>Patients with schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients without schizophrenia</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>GWAS</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group:</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kazakh population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persons of Kazakh nationality having this ethnicity in the 3rd generation&#xD;
&#xD;
          -  age from 18 to 65 years old;&#xD;
&#xD;
          -  the dispensary in a psychiatric institution at the place of residence with a diagnosis&#xD;
             of &quot;Paranoid schizophrenia&quot;;&#xD;
&#xD;
          -  the duration of the disease is at least 1 year (from the moment of taking under&#xD;
             dispensary supervision):&#xD;
&#xD;
          -  absence of severe and chronic somatic diseases;&#xD;
&#xD;
          -  absence of severe and chronic neurological diseases;&#xD;
&#xD;
          -  absence of comorbid drug addiction pathology;&#xD;
&#xD;
          -  signed informed consent to conduct this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd&#xD;
             generation&#xD;
&#xD;
          -  age less than 18 years old and over 65 years old;&#xD;
&#xD;
          -  those who are on dispensary registration in a psychiatric institution at the place of&#xD;
             residence with a diagnosis not related to ICD-10 under the heading F20.0 &quot;Paranoid&#xD;
             schizophrenia&quot;;&#xD;
&#xD;
          -  having a disease duration of less than 1 year (from the moment of taking under&#xD;
             dispensary supervision):&#xD;
&#xD;
          -  having severe and chronic somatic diseases;&#xD;
&#xD;
          -  having severe and chronic neurological diseases;&#xD;
&#xD;
          -  having comorbid narcological pathology;&#xD;
&#xD;
          -  not signed informed consent to conduct this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuanysh Altynbekov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Republican Scientific and Practical Center for Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuanysh Altynbekov, PhD</last_name>
    <phone>+77775001190</phone>
    <email>fakhradiyev.i@kaznmu.kz</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asfendiyarov Kazakh National Medical University</investigator_affiliation>
    <investigator_full_name>Ildar Fakhradiyev</investigator_full_name>
    <investigator_title>Head of the Laboratory of Experimental Medicine</investigator_title>
  </responsible_party>
  <keyword>GWAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

